W D Figg
Impact in
-
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
-
- Cancer, Lipids, and Metabolism
Papers in
-
- Biochemical and Molecular Research 1
-
- Lung Cancer Treatments and Mutations 1
- Co-authors
- A Tompkins (3 shared papers)E Reed (3 shared papers)David Köhler (2 shared papers)Paul H. Duray (2 shared papers)W. M. Linehan (1 shared paper)Selena Dixon (1 shared paper)Michael Hamilton (1 shared paper)James M. Pluda (1 shared paper)
- Journals
- Journal of Investigative Medicine (1 paper)Neuro-Oncology (1 paper)Clinical Pharmacology & Therapeutics (1 paper)Cancer Research (1 paper)Prostate Cancer and Prostatic Diseases (1 paper)
- Partner nations
- United StatesItalyUkraine
In The Last Decade
W D Figg
6 papers receiving 347 citations
Peers
Comparison fields: 5 of 44
- Pulmonary and Respiratory Medicine 190
- Cancer Research 83
- Hematology 60
- Oncology 77
- Molecular Biology 125
Countries citing papers authored by W D Figg
This map shows the geographic impact of W D Figg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W D Figg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W D Figg more than expected).
Fields of papers citing papers by W D Figg
This network shows the impact of papers produced by W D Figg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W D Figg. The network helps show where W D Figg may publish in the future.
Co-authors
The 25 scholars most cited alongside W D Figg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. | 2001 | 242 |
| 2 | A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. | 1999 | 79 |
| 3 | 1998 | 17 | |
| 4 | 2009 | 9 | |
| 5 | 1999 | 8 | |
| 6 | 2019 | 2 | |
| 7 | 2026 | 0 |
About W D Figg
W D Figg is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Oncology, Surgery and Genetics, having authored 7 papers that have together received 357 indexed citations. Recurring topics across this work include Estrogen and related hormone effects (1 paper), Drug-Induced Ocular Toxicity (1 paper), Genital Health and Disease (1 paper), Chronic Lymphocytic Leukemia Research (1 paper), Lung Cancer Treatments and Mutations (1 paper), Hormonal and reproductive studies (1 paper), Radiopharmaceutical Chemistry and Applications (1 paper) and Biochemical and Molecular Research (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (190 citations), Cancer Research (83 citations), Hematology (60 citations), Oncology (77 citations) and Molecular Biology (125 citations). W D Figg has collaborated with scholars based in United States, Italy and Ukraine. Frequent co-authors include A Tompkins, E Reed, David Köhler, Paul H. Duray, W. M. Linehan, Selena Dixon, Michael Hamilton, James M. Pluda, S. M. Steinberg and A Premkumar. Their work appears in journals such as Journal of Investigative Medicine, Neuro-Oncology, Clinical Pharmacology & Therapeutics, Cancer Research and Prostate Cancer and Prostatic Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.